| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryoelectron Microscopy | 20 | 2026 | 242 | 3.630 |
Why?
|
| Exercise | 19 | 2025 | 859 | 3.270 |
Why?
|
| Cancer Survivors | 9 | 2025 | 271 | 2.340 |
Why?
|
| Receptors, Opioid, mu | 4 | 2026 | 34 | 1.580 |
Why?
|
| Drug Discovery | 2 | 2022 | 178 | 1.300 |
Why?
|
| Weight Loss | 4 | 2023 | 525 | 1.270 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2023 | 296 | 1.140 |
Why?
|
| Receptors, Neurotensin | 2 | 2026 | 6 | 1.120 |
Why?
|
| Motivation | 4 | 2024 | 328 | 1.070 |
Why?
|
| Models, Molecular | 10 | 2026 | 1056 | 1.050 |
Why?
|
| Self Efficacy | 5 | 2021 | 204 | 1.000 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2026 | 8 | 0.970 |
Why?
|
| Hodgkin Disease | 3 | 2026 | 307 | 0.950 |
Why?
|
| Ions | 1 | 2025 | 24 | 0.920 |
Why?
|
| Water | 1 | 2025 | 185 | 0.840 |
Why?
|
| Ligands | 11 | 2025 | 486 | 0.830 |
Why?
|
| Overweight | 4 | 2022 | 376 | 0.820 |
Why?
|
| Molecular Dynamics Simulation | 3 | 2025 | 125 | 0.790 |
Why?
|
| Weight Reduction Programs | 2 | 2022 | 58 | 0.770 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 2603 | 0.730 |
Why?
|
| Social Media | 1 | 2024 | 119 | 0.730 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 5 | 2026 | 22 | 0.730 |
Why?
|
| Receptors, Somatostatin | 1 | 2022 | 55 | 0.720 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 109 | 0.690 |
Why?
|
| Mindfulness | 1 | 2021 | 30 | 0.670 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2021 | 45 | 0.650 |
Why?
|
| Text Messaging | 1 | 2020 | 42 | 0.640 |
Why?
|
| Mobile Applications | 1 | 2021 | 110 | 0.620 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 363 | 0.620 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2026 | 1276 | 0.600 |
Why?
|
| Proteins | 2 | 2025 | 1015 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 1312 | 0.590 |
Why?
|
| Neoplasms | 6 | 2025 | 2944 | 0.580 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 336 | 0.580 |
Why?
|
| Diet | 2 | 2023 | 1098 | 0.570 |
Why?
|
| Muscle Strength | 1 | 2018 | 82 | 0.530 |
Why?
|
| Urban Population | 2 | 2025 | 273 | 0.530 |
Why?
|
| Rural Population | 2 | 2025 | 262 | 0.510 |
Why?
|
| Analgesics, Opioid | 4 | 2026 | 480 | 0.490 |
Why?
|
| Guanosine Triphosphate | 2 | 2026 | 40 | 0.480 |
Why?
|
| Aging | 1 | 2023 | 1253 | 0.470 |
Why?
|
| Obesity | 5 | 2022 | 2379 | 0.470 |
Why?
|
| Health Behavior | 4 | 2020 | 388 | 0.460 |
Why?
|
| Humans | 50 | 2026 | 130433 | 0.450 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1604 | 0.430 |
Why?
|
| Signal Transduction | 10 | 2026 | 4674 | 0.420 |
Why?
|
| Middle Aged | 18 | 2026 | 28385 | 0.420 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 3 | 2024 | 32 | 0.420 |
Why?
|
| Schools | 4 | 2023 | 234 | 0.410 |
Why?
|
| Ipilimumab | 2 | 2026 | 62 | 0.400 |
Why?
|
| Aged | 13 | 2026 | 20895 | 0.390 |
Why?
|
| Protein Conformation | 3 | 2025 | 729 | 0.390 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2024 | 10 | 0.380 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 3 | 2024 | 20 | 0.370 |
Why?
|
| Hallucinogens | 3 | 2022 | 58 | 0.370 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2022 | 11 | 0.360 |
Why?
|
| Quality of Life | 3 | 2025 | 2071 | 0.350 |
Why?
|
| Ecological Momentary Assessment | 2 | 2022 | 10 | 0.350 |
Why?
|
| Protein Binding | 6 | 2026 | 1666 | 0.350 |
Why?
|
| Feasibility Studies | 4 | 2025 | 813 | 0.340 |
Why?
|
| Fitness Trackers | 2 | 2021 | 15 | 0.330 |
Why?
|
| Female | 23 | 2026 | 70291 | 0.300 |
Why?
|
| Adult | 15 | 2026 | 31128 | 0.300 |
Why?
|
| Smartphone | 2 | 2025 | 46 | 0.290 |
Why?
|
| Health Promotion | 2 | 2024 | 408 | 0.280 |
Why?
|
| Protein Multimerization | 4 | 2021 | 148 | 0.280 |
Why?
|
| beta-Arrestins | 3 | 2022 | 31 | 0.250 |
Why?
|
| Amino Acid Motifs | 1 | 2026 | 193 | 0.230 |
Why?
|
| Lysergic Acid Diethylamide | 2 | 2022 | 8 | 0.230 |
Why?
|
| HEK293 Cells | 2 | 2025 | 809 | 0.230 |
Why?
|
| Occupational Therapy | 1 | 2025 | 29 | 0.230 |
Why?
|
| Deception | 1 | 2025 | 10 | 0.220 |
Why?
|
| Analgesics | 1 | 2026 | 120 | 0.220 |
Why?
|
| Data Accuracy | 1 | 2025 | 31 | 0.220 |
Why?
|
| Survivorship | 1 | 2024 | 46 | 0.210 |
Why?
|
| Leisure Activities | 1 | 2023 | 10 | 0.200 |
Why?
|
| Molecular Docking Simulation | 2 | 2025 | 150 | 0.200 |
Why?
|
| Mexico | 1 | 2023 | 188 | 0.200 |
Why?
|
| Endocannabinoids | 1 | 2023 | 27 | 0.190 |
Why?
|
| Morphinans | 1 | 2022 | 2 | 0.190 |
Why?
|
| Cooking | 1 | 2023 | 37 | 0.190 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2022 | 5 | 0.190 |
Why?
|
| Crystallization | 1 | 2022 | 83 | 0.190 |
Why?
|
| Fatigue | 1 | 2024 | 195 | 0.190 |
Why?
|
| Biological Assay | 1 | 2023 | 106 | 0.190 |
Why?
|
| Workplace | 2 | 2022 | 82 | 0.190 |
Why?
|
| Pyrrolidines | 1 | 2022 | 46 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 149 | 0.190 |
Why?
|
| Entropy | 1 | 2022 | 28 | 0.190 |
Why?
|
| Fentanyl | 1 | 2022 | 55 | 0.180 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2021 | 6 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2021 | 11 | 0.180 |
Why?
|
| Telemedicine | 2 | 2025 | 511 | 0.180 |
Why?
|
| Magnesium | 1 | 2022 | 114 | 0.170 |
Why?
|
| Drug Design | 1 | 2022 | 161 | 0.170 |
Why?
|
| Oxytocin | 1 | 2022 | 69 | 0.170 |
Why?
|
| Male | 16 | 2026 | 64535 | 0.170 |
Why?
|
| Survivors | 1 | 2024 | 346 | 0.170 |
Why?
|
| School Teachers | 1 | 2021 | 10 | 0.170 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2021 | 48 | 0.170 |
Why?
|
| Technology | 1 | 2021 | 69 | 0.170 |
Why?
|
| Receptors, GABA-B | 1 | 2020 | 11 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2020 | 15 | 0.160 |
Why?
|
| Quantum Theory | 1 | 2020 | 19 | 0.160 |
Why?
|
| Lipids | 2 | 2024 | 563 | 0.160 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 80 | 0.160 |
Why?
|
| beta-Arrestin 1 | 1 | 2020 | 4 | 0.160 |
Why?
|
| Calcium | 2 | 2024 | 1027 | 0.160 |
Why?
|
| Binding Sites | 4 | 2025 | 1149 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 328 | 0.150 |
Why?
|
| Teaching | 1 | 2021 | 198 | 0.150 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2019 | 1 | 0.150 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1485 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1258 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 120 | 0.150 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2019 | 13 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 124 | 0.150 |
Why?
|
| Affect | 1 | 2020 | 165 | 0.150 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2019 | 25 | 0.150 |
Why?
|
| Models, Psychological | 1 | 2019 | 137 | 0.150 |
Why?
|
| Peptides | 4 | 2023 | 708 | 0.150 |
Why?
|
| Students | 1 | 2021 | 247 | 0.150 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 480 | 0.140 |
Why?
|
| Cholesterol | 1 | 2021 | 540 | 0.140 |
Why?
|
| Health Surveys | 1 | 2019 | 255 | 0.140 |
Why?
|
| Cognition | 1 | 2023 | 813 | 0.140 |
Why?
|
| Animals | 9 | 2026 | 33907 | 0.140 |
Why?
|
| Substrate Specificity | 3 | 2024 | 285 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 4001 | 0.130 |
Why?
|
| Glucose | 1 | 2021 | 854 | 0.130 |
Why?
|
| Pandemics | 2 | 2021 | 1153 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 561 | 0.120 |
Why?
|
| Linear Models | 1 | 2018 | 688 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 435 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2018 | 271 | 0.110 |
Why?
|
| Adolescent | 3 | 2026 | 20753 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 1443 | 0.110 |
Why?
|
| Communication | 1 | 2019 | 531 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 682 | 0.110 |
Why?
|
| Cell Membrane | 3 | 2022 | 451 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1231 | 0.110 |
Why?
|
| Collagen Type VI | 1 | 2014 | 7 | 0.110 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2014 | 9 | 0.110 |
Why?
|
| Hemocyanins | 1 | 2014 | 23 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 68 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2014 | 32 | 0.100 |
Why?
|
| Sleep | 3 | 2022 | 370 | 0.100 |
Why?
|
| Young Adult | 2 | 2026 | 9995 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2023 | 5069 | 0.100 |
Why?
|
| Physical Education and Training | 2 | 2023 | 14 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 190 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2023 | 307 | 0.090 |
Why?
|
| Allosteric Regulation | 2 | 2024 | 58 | 0.090 |
Why?
|
| Nanostructures | 2 | 2024 | 65 | 0.090 |
Why?
|
| GTP-Binding Proteins | 2 | 2022 | 160 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 1263 | 0.090 |
Why?
|
| Pain | 2 | 2026 | 428 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 341 | 0.080 |
Why?
|
| Serotonin | 2 | 2022 | 210 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6781 | 0.080 |
Why?
|
| Protein Stability | 2 | 2020 | 165 | 0.070 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2016 | 675 | 0.070 |
Why?
|
| Protein Domains | 2 | 2020 | 253 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3803 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2026 | 38 | 0.060 |
Why?
|
| Mice | 4 | 2026 | 18197 | 0.060 |
Why?
|
| Nucleus Accumbens | 1 | 2026 | 56 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2026 | 155 | 0.060 |
Why?
|
| Oklahoma | 1 | 2024 | 9 | 0.060 |
Why?
|
| Dopamine | 1 | 2026 | 251 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1543 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2004 | 124 | 0.050 |
Why?
|
| Polyamines | 1 | 2024 | 37 | 0.050 |
Why?
|
| Tryptophan | 1 | 2024 | 82 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2026 | 320 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2026 | 1112 | 0.050 |
Why?
|
| Arrestins | 1 | 2022 | 25 | 0.050 |
Why?
|
| Nociception | 1 | 2022 | 13 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 163 | 0.050 |
Why?
|
| Chemotactic Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2022 | 37 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2022 | 44 | 0.050 |
Why?
|
| Cell Line | 2 | 2020 | 2579 | 0.050 |
Why?
|
| Receptors, Vasopressin | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cations | 1 | 2022 | 38 | 0.050 |
Why?
|
| Receptors, Oxytocin | 1 | 2022 | 21 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2021 | 11 | 0.050 |
Why?
|
| Receptors, Peptide | 1 | 2022 | 56 | 0.050 |
Why?
|
| United States | 3 | 2025 | 11827 | 0.040 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2021 | 37 | 0.040 |
Why?
|
| Saccharomycetales | 1 | 2021 | 37 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 109 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2022 | 132 | 0.040 |
Why?
|
| School Health Services | 1 | 2022 | 100 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2025 | 1452 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2023 | 326 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1323 | 0.040 |
Why?
|
| Ion Channel Gating | 1 | 2021 | 121 | 0.040 |
Why?
|
| Methiothepin | 1 | 2020 | 1 | 0.040 |
Why?
|
| Spodoptera | 1 | 2020 | 29 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2020 | 17 | 0.040 |
Why?
|
| GABA-B Receptor Antagonists | 1 | 2020 | 1 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12860 | 0.040 |
Why?
|
| Recurrence | 2 | 2020 | 1482 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2020 | 78 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 280 | 0.040 |
Why?
|
| Social Isolation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Receptors, Glutamate | 1 | 2020 | 18 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 61 | 0.040 |
Why?
|
| Neutrophils | 1 | 2022 | 359 | 0.040 |
Why?
|
| Rats | 1 | 2026 | 3398 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2020 | 92 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 100 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2020 | 160 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 555 | 0.040 |
Why?
|
| Sf9 Cells | 1 | 2019 | 11 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2019 | 7 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 35 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 140 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 552 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 236 | 0.040 |
Why?
|
| Cannabinoids | 1 | 2019 | 32 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 229 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 325 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 669 | 0.030 |
Why?
|
| Cysteine | 1 | 2019 | 137 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2020 | 714 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 2020 | 221 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2022 | 544 | 0.030 |
Why?
|
| Feedback | 1 | 2018 | 148 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1164 | 0.030 |
Why?
|
| Intention | 1 | 2017 | 101 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2022 | 984 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 676 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 349 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2026 | 4699 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 232 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 1577 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1493 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2131 | 0.030 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1587 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2207 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 687 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 695 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 238 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 189 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 232 | 0.020 |
Why?
|
| Monocytes | 1 | 2014 | 336 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3626 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 436 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1065 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1627 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1395 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 895 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7381 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2014 | 753 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 1152 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 6131 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 135 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 238 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 900 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1498 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 13269 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 17615 | 0.010 |
Why?
|
| Child | 1 | 2016 | 26166 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6190 | 0.010 |
Why?
|